Risk Minimisation Material: Mayzent (siponimod) - Prescriber Checklist
This guide provides information on the most important risks associated with siponimod (e.g. bradycardia, hypertension and deranged LFTs) and the activities required to minimise these risks. Guidance on dosing and monitoring treatment is also provided.
Source:
electronic Medicines compendium
SPS commentary:
An information leaflet for female patients of childbearing potential (should not be used in pregnant women or in women of childbearing potential not using effective contraception), and a patient and caregiver guide have also been produced